Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions
Vip Viprakasit(Siriraj Hospital), Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Tatiana Zinger(Incyte (United States)), Abderrahim Khélif(Ente Ospedaliero Ospedali Galliera), Silverio Perrotta(University Hospital Foundation), John B. Porter(Royal London Hospital), Jeevan K. Shetty(Ente Ospedaliero Ospedali Galliera), Antonio Piga(University of Turin), Antonis Kattamis, Abderrahmane Laadem(Daiichi Sankyo (India)), Kevin H.M. Kuo(University Health Network), Olivier Hermine(Centre National de la Recherche Scientifique), Alì Taher(American University of Beirut Medical Center), Thomas D. Coates(Children's Hospital of Los Angeles), Wen‐Ling Kuo(Chang Gung University), Dimana Miteva(Bristol-Myers Squibb (Switzerland)), Hong Keng Liew(Hospital Sultanah Bahiyah), Daniel Sinsimer, Peter G. Linde(Ente Ospedaliero Ospedali Galliera), Ersi Voskaridou(Laiko General Hospital of Athens)
Cited by 3
Related Papers
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777
Thalassaemia
|The Lancet|2017|763
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
|New England Journal of Medicine|2007|520